<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2802244997
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2003
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        XALACOM EYE DROP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TIMOLOL MALEATE,LATANOPROST
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5,0.05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        33.4
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Pfizer Manufacturing Belgium N.V." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Pfizer Manufacturing Belgium N.V.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Upjohn SRL
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01ED51
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xalacom contains two medicines: latanoprost and timolol. Latanoprost belongs to a group of medicines known as prostaglandin analogues. Timolol belongs to a group of medicines known as beta-blockers. Latanoprost works by increasing the natural outflow of fluid from the eye into the bloodstream. Timolol works by slowing the formation of fluid in the eye.</p><p>Xalacom is used to reduce the pressure in your eye if you have conditions known as open angle glaucoma or ocular hypertension. Both these conditions are linked to an increase in the pressure within your eye, eventually affecting your eyesight. Your doctor will usually prescribe you Xalacom when other medicines have not worked adequately.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Xalacom can be used in adult men and women (including the elderly), but is not recommended for use if you are less than 18&nbsp;years of age.</p><p>&nbsp;</p><p>Do not use Xalacom</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic (hypersensitive) to either of the medicines in Xalacom (latanoprost or timolol), beta-blockers, or any of the other ingredients of Xalacom (listed in section&nbsp;6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have now or have had in past respiratory problems such as asthma, severe chronic obstructive bronchitis (severe lung disease which may cause wheeziness, difficulty in breathing and/or long-standing cough).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have serious heart problems or heart rhythm disorders.</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p>Talk to your doctor or pharmacist before using Xalacom if you have now or have had in the past:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coronary heart disease (symptoms can include chest pain or tightness, breathlessness or choking), heart failure, low blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disturbances of heart rate such as slow heart beat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breathing problems, asthma or chronic obstructive pulmonary disease.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Poor blood circulation disease (such as Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes as timolol may mask signs and symptoms of low blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Overactivity of the thyroid gland as timolol may mask signs and symptoms.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You are about to have any kind of eye surgery (including cataract surgery) or have had any kind of eye surgery in the past.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You suffer from eye problems (such as eye pain, eye irritation, eye inflammation or blurred vision).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You know that you suffer from dry eyes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You wear contact lenses. You can still use Xalacom but follow the instructions for contact lens wearers in section&nbsp;3.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You know that you suffer from angina (particularly a type known as Prinzmetal angina).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You know that you suffer from severe allergic reactions that would usually require hospital treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You have suffered or are currently suffering from a viral infection of the eye caused by the herpes simplex virus (HSV).</p><p>&nbsp;</p><p>Tell your doctor before you have an operation that you are using Xalacom<strong> </strong>as timolol may change effects of some medicines used during anaesthesia.</p><p>&nbsp;</p><p><strong>Other medicines and Xalacom</strong></p><p>&nbsp;</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including using eye drops and medicines obtained without a prescription.</p><p>Xalacom can affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma. Tell your doctor if you are using or intend to use medicines to lower blood pressure, heart medicine or medicines to treat diabetes.</p><p>&nbsp;</p><p>In particular, speak to your doctor or pharmacist if you know that you are taking any of the following types of medicine:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prostaglandins, prostaglandin analogues or prostaglandin derivates.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Epinephrine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs used to treat high blood pressure such as oral calcium channel blockers, guanethidine, antiarrythmics, digitalis glycosides or parasympathomimetics.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Quinidine (used to treat heart conditions and some types of malaria).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Antidepressants known as fluoxetine and paroxetine.</p><p>&nbsp;</p><p>Xalacom with food and drink</p><p>&nbsp;</p><p>Normal meals, food or drink have no effect on when or how you should use Xalacom.</p><p>Pregnancy, breast-feeding and fertility</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>Do not use Xalacom if you are pregnant unless your doctor considers it necessary. Tell your doctor immediately if you are pregnant, think you are pregnant or are planning to become pregnant.</p><p><strong>&nbsp;</strong></p><p><u>Breast-feeding</u></p><p>Do not use Xalacom if you are breast-feeding. Xalacom may get into your milk. Ask your doctor for advice before taking any medicine during breast-feeding.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p>Latanoprost and timolol have been found to have no effect on male or female fertility in animal studies.</p><p>&nbsp;</p><p>Driving and using machines</p><p>When you use Xalacom your vision may become blurred for a short time. If this happens to you, do not drive or use any tools or machines until your vision becomes clear again.</p><p>&nbsp;</p><p><strong>Xalacom</strong><strong> contains benzalkonium chloride and </strong>phosphate buffers</p><p>This medicine contains 0.2&nbsp;mg benzalkonium chloride in each millilitre.</p><p>&nbsp;</p><p>Benzalkonium chloride may be absorbed by soft contact lenses and may change the colour of the contact lenses. You should remove contact lenses before using this medicine and put them back 15&nbsp;minutes afterwards.</p><p>&nbsp;</p><p>Benzalkonium chloride may also cause eye irritation, especially if you have dry eyes or disorders of the cornea (the clear layer at the front of the eye). If you feel abnormal eye sensation, stinging or pain in the eye after using this medicine, talk to your doctor.</p><p>&nbsp;</p><p>This medicine contains 6.3&nbsp;mg phosphates in each millilitre which is equivalent to 0.2&nbsp;mg per drop.</p><p>&nbsp;</p><p>If you suffer from severe damage to the clear layer at the front of the eye (the cornea), phosphates may cause in very rare cases cloudy patches on the cornea due to calcium build‑up during treatment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose for adults (including the elderly) is one drop once a day in the affected eye(s).</p><p>Do not use Xalacom more than once a day, because the effectiveness of the treatment can be reduced if you administer it more often.</p><p>Use Xalacom as instructed by your doctor until your doctor tells you to stop.</p><p>Your doctor may want you to have extra checks on your heart and circulation if you use Xalacom.</p><p>&nbsp;</p><p>Contact lens wearers</p><p>&nbsp;</p><p>If you wear contact lenses, you should remove them before using Xalacom. After using Xalacom you should wait 15&nbsp;minutes before putting your contact lenses back in.</p><p>Instructions for use</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Wash your hands and sit or stand comfortably.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Twist off the outer cap (which can be thrown away).</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><strong>Figure</strong> <!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:11.0pt;
  mso-ansi-language:EN-GB'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC <span style='mso-element:
  field-separator'></span></span></b><![endif]--><strong>1</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:11.0pt;
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Unscrew the protective inner cap. The protective cap should be retained.</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Figure <!--[if supportFields]><span lang=EN-GB
  style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ansi-language:
  EN-GB'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC <span style='mso-element:
  field-separator'></span></span><![endif]-->2<!--[if supportFields]><span
  lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif;
  mso-ansi-language:EN-GB'><span style='mso-element:field-end'></span></span><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use your finger to gently pull down the lower eyelid of your affected eye.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Place the tip of the bottle close to, but not touching your eye.</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Squeeze the bottle gently so that only one drop goes into your eye, then release the lower eyelid.</p><p>&nbsp;</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; After using Xalacom, press a finger into the corner of your eye, by the nose (figure&nbsp;4) for 2&nbsp;minutes. This helps to stop latanoprost + timolol getting into the rest of the body.</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Figure 3</p><p>&nbsp;</p><p><strong>Figure 4</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Repeat in your other eye if your doctor has told you to do this.</p><p>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Put the protective inner cap back on the bottle.</p></td></tr></tbody></table><p>If you use Xalacom with other eye drops</p><p>Wait at least 5&nbsp;minutes between using Xalacom and using the other eye drops.</p><p>&nbsp;</p><p>If you use more Xalacom than you should</p><p>If you put too many drops in your eye you may experience some minor irritation in your eye and your eyes may water and turn red. This should pass but if you are worried contact your doctor for advice.</p><p>&nbsp;</p><p>If you swallow Xalacom</p><p>If you swallow Xalacom accidentally you should contact your doctor for advice. If you swallow a lot of Xalacom you may feel sick, have stomach pains, feel tired, flushed and dizzy and start to sweat.</p><p>&nbsp;</p><p>If you forget to use Xalacom</p><p>Carry on with the usual dosage at the usual time. Do not use a double dose to make up to the dose you have forgotten. If you are unsure about anything talk to your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines this medicine can cause side effects, although not everybody gets them.</p><p>You can usually carry on using the drops, unless the effects are serious. If you&#39;re worried, talk to a doctor or pharmacist. Do not stop using Xalacom without speaking to your doctor.</p><p>&nbsp;</p><p>Listed below are the known side effects of using Xalacom. The most important side-effect is the possibility of a gradual, permanent change in your eye colour. It is also possible that Xalacom might cause serious changes in the way your heart works. If you notice changes in your heart rate or heart function you should speak to a doctor and tell them you have been using Xalacom.</p><p>&nbsp;</p><p>The following are known side effects of using Xalacom:</p><p>&nbsp;</p><p>Very common (may affect more than 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A gradual change in your eye colour by increasing the amount of brown pigment in the coloured part of the eye known as the iris. If you have mixed-colour eyes (blue-brown, grey-brown, yellow-brown or green-brown) you are more likely to see this change than if you have eyes of one colour (blue, grey, green or brown eyes). Any changes in your eye colour may take years to develop. The colour change may be permanent and may be more noticeable if you use Xalacom in only one eye. There appears to be no problems associated with the change in eye colour. The eye colour change does not continue after Xalacom treatment is stopped.</p><p>&nbsp;</p><p>Common (may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye irritation (a feeling of burning, grittiness, itching, stinging or the sensation of a foreign body in the eye) and eye pain.</p><p>&nbsp;</p><p>Uncommon (may affect up to 1 in 100 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Redness of the eye, eye infection (conjunctivitis), blurred vision, watery eyes, inflammation of the eyelids, irritation or disruption of the surface of the eye</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rashes or itching (pruritus)</p><p>&nbsp;</p><p>Other side effects</p><p>Like other medicines used in the eyes, Xalacom (latanoprost and timolol) is absorbed into the blood. The incidence of side effects after using eye drops is lower than when medicines are, for example, taken by mouth or injected.</p><p>Although not seen with Xalacom, the following additional side effects have been seen with the medicines in Xalacom (latanoprost and timolol) and therefore might occur when you use Xalacom. The listed side effects include reactions seen within the class of beta-blockers (e.g. timolol) when used for treating eye conditions:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, vomiting (uncommon).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developing a viral infection of the eye caused by the herpes simplex virus (HSV).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Generalized allergic reactions including swelling beneath the skin that can occur in areas such as the face and limbs and can obstruct the airway which may cause difficulty swallowing or breathing, hives or itchy rash, localized and generalized rash, itchiness, severe sudden life‑threatening allergic reaction.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood glucose levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping (insomnia), depression, nightmares, memory loss, hallucinations.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fainting, stroke, reduced blood supply to the brain, increases in signs and symptoms of myasthenia gravis (muscle disorder), unusual sensations like pins and needles, and headache.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling at the back of the eye (macular oedema), fluid filled cyst within the coloured part of the eye (iris cyst), light sensitivity (photophobia), sunken eye appearance (deepening of the eye sulcus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Signs and symptoms of eye irritation (e.g. burning, stinging, itching, tearing, redness), inflammation of the eyelid, inflammation in the cornea, blurred vision and detachment of the layer below the retina that contains blood vessels following filtration surgery which may cause visual disturbances, decreased corneal sensitivity, dry eyes, corneal erosion (damage to the front layer of the eyeball), drooping of the upper eyelid (making the eye stay half closed), double vision.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Darkening of the skin around the eyes, changes to the eyelashes and fine hairs around the eye (increased number, length, thickness and darkening), changes to the direction of eyelash growth, swelling around the eye, swelling of the coloured part of the eye (iritis/uveitis), scarring of the surface of the eye.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Whistling/ringing in the ears (tinnitus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Angina, worsening of angina in patients who already have heart disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Slow heart rate, chest pain, palpitations (awareness of heart rhythm), oedema (fluid build‑up), changes in the rhythm or speed of the heartbeat, congestive heart failure (heart disease with shortness of breath and swelling of the feet and legs due to fluid build‑up), a type of heart rhythm disorder, heart attack, heart failure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure, poor blood circulation which makes the fingers and toes numb and pale, cold hands and feet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath, constriction of the airways in the lungs (predominantly in patients with pre‑existing disease), difficulty breathing, cough, asthma, worsening of asthma.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Taste disturbances, indigestion, diarrhoea, dry mouth, abdominal pain.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair loss, skin rash with white silvery coloured appearance (psoriasiform rash) or worsening of psoriasis, skin rash.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Joint pain, muscle pain not caused by exercise, muscle weakness, tiredness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sexual dysfunction, decreased libido.</p><p>&nbsp;</p><p>In very rare cases, some patients with severe damage to the clear layer at the front of the eye (the cornea) have developed cloudy patches on the cornea due to calcium build-up during treatment.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects talk to your doctor, pharmacist This includes any possible side effect not listed in this leaflet. You can also report side effects directly via local reporting system.</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report side effects</strong></p><p>&nbsp;</p><ul><li><strong>Saudi Arabia</strong></li></ul><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><ul><li>SFDA Call center : 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa/</li></ul></td></tr></tbody></table><p>&nbsp;</p><ul><li><strong>&nbsp;&nbsp;&nbsp; Other GCC States</strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated after EXP on the carton and bottle label. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Shelf life: 36 months</p><p>Store the unopened bottle of Xalacom in a refrigerator (between 2&deg;C to 8&deg;C). After opening the bottle it is not necessary to store it in a refrigerator but do not store it above 25&deg;C.</p><p>After opening do not use this bottle for more than 4&nbsp;weeks. When you are not using Xalacom, keep the bottle in the outer carton, in order to protect from light.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substances are latanoprost 50&nbsp;micrograms/mL and timolol (as timolol maleate) 5&nbsp;mg/mL</p><p>&nbsp;</p><p>The other ingredients are:</p><p>Benzalkonium chloride</p><p>Disodium phosphate Anhydrous</p><p>Sodium Dihydrogen Phosphate Monohydrate</p><p>Sodium Chloride</p><p>Hydrochloric acid solution (for adjustment to pH 6.0)</p><p>Sodium hydroxide solution (for adjustment to pH 6.0)</p><p>Water for injections</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Each bottle contains 2.5 mL of Xalacom eye drops.

Xalacom is a clear, colourless liquid.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:<em> </em></strong></p><p>UpjohnSRL,,&nbsp; Boulevard de la Plaine 17, 1050 &nbsp;Bruxelles, Belgium.</p><p>&nbsp;</p><p><strong>Manufacturer: </strong></p><p>Pfizer Manufacturing Belgium NV, Rijksweg 12, 2870 Puurs, Belgium.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                a-   This leaflet was last revised in June 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي زالاكوم على دواءين: لاتانوبروست وتيمولول.&nbsp; ينتمي لاتانوبروست إلى مجموعة من الأدوية تُعرف باسم نظائر البروستاجلاندين. وينتمي تيمولول إلى مجموعة من الأدوية تُعرف باسم حاصرات بيتا. يعمل لاتانوبروست عن طريق زيادة التدفق الطبيعي للسوائل من داخل العين إلى مجرى الدم. ويعمل تيمولول عن طريق إبطاء عملية تكوّن السوائل في العين.</p><p dir="RTL">يُستخدم زالاكوم لتقليل الضغط داخل عينك إذا كنت تعاني من حالتين تُعرفان باسم الزرق مفتوح الزاوية أو ارتفاع ضغط الدم داخل العين. ترتبط كل من هاتين الحالتين بوجود زيادة في الضغط داخل عينك، مما يؤثر في نهاية المطاف على بصرك. عادةً ما سيصف لك طبيبك زالاكوم إذا لم تكن الأدوية الأخرى فعالة بشكل كاف.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن استخدام زالاكوم مع البالغين من الرجال والسيدات (بما في ذلك المسنين)، ولكن لا يوصى باستخدامه إذا كان عمرك أقل من 18 عامًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>موانع استعمال زالاكوم:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا بالحساسية (فرط الحساسية) تجاه أي من الدواءين الموجودين في زالاكوم (لاتانوبروست أو تيمولول)، أو حاصرات بيتا، أو أي من مكونات زالاكوم الأخرى (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مصابًا الآن أو كنت قد أصبت في الماضي بمشكلات تنفسية مثل الربو، الالتهاب الشعبي الانسدادي المزمن الشديد (مرض رئوي شديد قد يسبب أزيزًا، و/أو صعوبة في التنفس، و/أو سعالًا يستمر لفترة طويلة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت مُصابًا بمشكلات قلبية خطيرة أو اضطرابات في ضربات القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات عند استعمال زالاكوم:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث مع طبيبك أو الصيدلي قبل استخدام زالاكوم إذا كنت تعاني الآن أو سبق أن عانيت مما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض القلب التاجي (يمكن أن تتضمن الأعراض ألم أو ضيق الصدر، أو انقطاع النفس، أو الاختناق)، فشل القلب، ضغط الدم المنخفض.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في معدل نبضات القلب مثل بطء ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات التنفس، أو الربو، أو مرض الانسداد الرئوي المزمن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض ضعف الدورة الدموية (مثل مرض رينو أو متلازمة رينو).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري، حيث قد يحجب تيمولول علامات وأعراض انخفاض سكر الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط نشاط الغدة الدرقية، حيث قد يحجب تيمولول علامات وأعراض هذه الحالة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت على وشك الخضوع لأي نوع من جراحات العيون (بما في ذلك جراحة علاج إعتام عدسة العين)، أو إذا كنت قد خضعت في السابق لأي نوع من جراحات العيون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات في العين (مثل ألم العين، أو تهيج العين، أو التهاب العين، أو تغيم الرؤية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنك تعاني من جفاف العينين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تضع عدسات لاصقة. لا يزال بإمكانك استخدام زالاكوم، ولكن اتبع التعليمات الموجهة لمستخدمي العدسات اللاصقة في القسم 3.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنك تعاني من ذبحة صدرية (وخاصةً من نوع يُعرف باسم ذبحة برنزميتال).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعلم أنك تعاني من تفاعلات حساسية شديدة تتطلب عادةً علاجًا بالمستشفى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل أو تعاني حاليًا من عدوى فيروسية في العين سبّبها فيروس الهربس البسيط (HSV).</p><p dir="RTL">أخبر طبيبك قبل خضوعك لعملية جراحية أنك تستخدم زالاكوم،<strong> </strong>حيث قد يغير تيمولول من تأثيرات بعض الأدوية المستخدمة أثناء التخدير.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التداخلات الدوائية من أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، أو تناولت مؤخرًا، أو قد تتناول أي أدوية أخرى، بما في ذلك استخدام قطرات العين والأدوية التي يتم الحصول عليها دون وصفة طبية.</p><p dir="RTL">يمكن أن يؤثر زالاكوم على الأدوية الأخرى التي تستخدمها أو يمكن أن يتأثر بها، بما في ذلك قطرات العين الأخرى المستخدمة لعلاج الزرق. أخبر طبيبك إذا كنت تستخدم أو تنوي استخدام أدوية لخفض ضغط الدم، أو أدوية القلب، أو أدوية لعلاج داء السكري.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، تحدث إلى طبيبك أو الصيدلي إذا كنت تعلم أنك تتناول أيًا من أنواع الدواء التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البروستاجلاندينات، أو نظائر البروستاجلاندين، أو مشتقات البروستاجلاندين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إبينفرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير المستخدمة لعلاج ضغط الدم المرتفع مثل حاصرات قنوات الكالسيوم التي تؤخذ عن طريق الفم، أو جوانيثيدين، أو مضادات اضطراب ضربات القلب، أو الجليكوزيدات المستخرجة من نبات الديجيتال، أو مُنبهات العصب نظير السمباثاوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كينيدين (يستخدم لعلاج الحالات القلبية وبعض أنواع الملاريا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الاكتئاب المعروفة باسم فلوكسيتين وباروكسيتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول زالاكوم مع الطعام والشراب</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تؤثر الوجبات، أو الأطعمة، أو المشروبات المعتادة على الوقت الذي ينبغي أن تستخدم فيه زالاكوم أو على كيفية استخدامك له.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة</strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تستخدمي زالاكوم إذا كنتِ حاملًا إلا إذا رأى طبيبكِ أن ذلك ضروري. أخبري طبيبكِ فورًا إذا كنتِ حاملًا، أو تعتقدين أنكِ حامل، أو تخططين للحمل.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الرضاعة</u></p><p dir="RTL">لا تستخدمي زالاكوم إذا كنتِ تُرضعين رضاعة طبيعية. قد يمر زالاكوم إلى لبن الثدي لديكِ. استشيري طبيبكِ قبل تناول أي دواء أثناء الرضاعة الطبيعية.</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><u>الخصوبة</u></p><p dir="RTL">لقد وُجد أن لاتانوبروست وتيمولول ليس لهما أي تأثير على خصوبة الذكور أو الإناث في الدراسات التي أجريت على الحيوانات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تأثير زالاكوم على القيادة واستخدام الآلات</strong></p><p dir="RTL">عندما تستخدم زالاكوم، قد تصبح رؤيتك متغيمة لفترة قصيرة. إذا حدث لك هذا، فلا تقم بالقيادة أو استخدام أي أدوات أو آلات حتى تصبح رؤيتك واضحة مرة أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات زالاكوم</strong></p><p dir="RTL"><strong>يحتوي زالاكوم على كلوريد البنزالكونيوم وعوامل الفوسفات المثبتة</strong></p><p dir="RTL">يحتوي هذا الدواء على 0.2 ملجم من كلوريد البنزالكونيوم في كل ملليلتر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يتم امتصاص كلوريد البنزالكونيوم بواسطة العدسات اللاصقة اللينة وقد يغير لونها. ينبغي أن تنزع العدسات اللاصقة قبل استخدام هذا الدواء وتضعها مرة أخري بعد مرور 15 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يسبب كلوريد البنزالكونيوم أيضًا تهيج العينين، خاصة إذا كنت مصابًا بجفاف العينين أو اضطرابات القرنية (الطبقة الشفافة في مقدمة العين). إذا شعرت بإحساس غير طبيعي في العين، أو وخز أو ألم في العين بعد استخدام هذا الدواء، فتحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي هذا الدواء على 6.3 ملجم من الفوسفاتاز بكل ملليلتر بما يكافئ 0.2 ملجم لكل قطرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تعاني من تلف شديد بالطبقة الشفافة في مقدمة العين (القرنية)، فقد يتسبب الفوسفات في ظهور بقع غيمية على القرنية في حالات نادرة جدًا، وذلك بسبب تراكم الكالسيوم أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احرص دومًا على استخدام هذا الدواء تمامًا كما أخبرك طبيبك أو الصيدلي. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا مما يجب عليك فعله.</p><p dir="RTL">الجرعة الموصى بها للبالغين (بما في ذلك المسنين) هي قطرة واحدة في العين المصابة (العينين المصابتين) مرة واحدة يوميًا.</p><p dir="RTL">لا تستخدم زالاكوم أكثر من مرة واحدة يوميًا لأن فعالية العلاج يمكن أن تنخفض إذا استخدمته بمعدل أكثر تكرارًا.</p><p dir="RTL">استخدم زالاكوم وفقًا لتعليمات طبيبك إلى أن يخبرك طبيبك بالتوقف.</p><p dir="RTL">قد يرغب طبيبك في إجراء فحوصات إضافية لقلبك ودورتك الدموية إذا استخدمت زالاكوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مستخدمو العدسات اللاصقة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تضع عدسات لاصقة، ينبغي أن تنزعها قبل استخدام زالاكوم. بعد استخدام زالاكوم، ينبغي أن تنتظر لمدة 15 دقيقة قبل وضع عدساتك اللاصقة مرة أخرى.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>تعليمات الاستخدام</strong></p><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اغسل يديك واجلس أو قف في وضع مريح.</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدِر الغطاء الخارجي لنزعه (يمكن التخلص منه).</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشكل</strong> <!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:11.0pt;
  font-family:"Times New Roman",serif'><span style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC <span style='mso-element:
  field-separator'></span></span></b><![endif]--><strong>1</strong><!--[if supportFields]><b
  style='mso-bidi-font-weight:normal'><span dir=LTR style='font-size:11.0pt;
  font-family:"Times New Roman",serif'><span style='mso-element:field-end'></span></span></b><![endif]--></p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قم بفك الغطاء الداخلي الواقي. ينبغي الاحتفاظ بالغطاء الواقي.</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">الشكل <!--[if supportFields]><span
  lang=AR-SA style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
  style='mso-element:field-begin'></span><span
  style='mso-spacerun:yes'> </span>SEQ Figure \* ARABIC <span style='mso-element:
  field-separator'></span></span><![endif]-->2<!--[if supportFields]><span
  lang=AR-SA style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
  style='mso-element:field-end'></span></span><![endif]--></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><table dir="rtl" border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدم إصبعك لتسحب الجفن السفلي لعينك المصابة برفق إلى أسفل.</p><p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضع طرف الزجاجة بالقرب من عينك ولكن دون أن يلمسها.</p><p dir="RTL">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضغط على الزجاجة برفق حتى تدخل قطرة واحدة فقط في عينك، ثم حرر الجفن السفلي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد استخدام زالاكوم، اضغط بأحد الأصابع على زاوية عينك المجاورة للأنف (الشكل 4) لمدة دقيقتين. يساعد هذا على منع دخول لاتانوبروست + تيمولول إلى باقي الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p><p dir="RTL">الشكل 3</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشكل 4</strong></p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كرر الأمر في عينك الأخرى إذا كان طبيبك قد أخبرك أن تفعل هذا.</p><p dir="RTL">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعِد وضع الغطاء الداخلي الواقي على الزجاجة.</p></td></tr></tbody></table><p dir="RTL"><strong>&nbsp;</strong></p><p>&nbsp;</p><p dir="RTL"><strong>إذا كنت تستخدم زالاكوم مع أنواع أخرى من قطرات العين</strong></p><p dir="RTL">انتظر لمدة خمس دقائق على الأقل بين استخدام زالاكوم واستخدام قطرات العين الأخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة الزائدة من زالاكوم</strong></p><p dir="RTL">إذا وضعت عدد قطرات أكبر مما ينبغي في عينك، فقد تشعر بتهيج طفيف في عينك ويمكن أن تدمع عيناك ويصبح لونهما أحمر. من المفترض أن تزول هذه الأعراض، ولكن إذا شعرت بالقلق فتواصل مع طبيبك لاستشارته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا ابتلعت زالاكوم</strong></p><p dir="RTL">إذا ابتلعت زالاكوم بشكل عرضي، ينبغي أن تتواصل مع طبيبك لاستشارته. إذا ابتلعت كمية كبيرة من زالاكوم، فقد تشعر ببرغبة في التقيؤ، وتصاب بآلام في المعدة، وتشعر بالتعب، وهبات الحرارة، والدوار وتبدأ في التعرق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نسيان تناول جرعة زالاكوم</strong></p><p dir="RTL">استمر في الاستخدام بالجرعة المعتادة في الوقت المعتاد. لا تستخدم جرعة مضاعفة لتعويض الجرعة التي نسيتها. إذا كنت غير متأكد بشأن أي شيء، فتحدث إلى طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال بالنسبة لجميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، غير أنها لا تصيب الجميع.</p><p dir="RTL">في المعتاد، يمكنك الاستمرار في استخدام القطرات، ما لم تكن الآثار خطيرة. إذا كنت تشعر بالقلق، فتحدث إلى طبيبك أو الصيدلي. لا تتوقف عن استخدام زالاكوم دون التحدث إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدرج أدناه الآثار الجانبية المعروفة لاستخدام زالاكوم. الأثر الجانبي الأهم هو احتمال تغير لون عينك تدريجيًا وبصورة دائمة. من المحتمل أيضًا أن يسبب زالاكوم تغيرات خطيرة في الطريقة التي يعمل بها قلبك. إذا لاحظت تغيرات في معدل نبضات قلبك أو وظائف قلبك، ينبغي أن تتحدث إلى طبيب وتخبره بأنك تستخدم زالاكوم.</p><p dir="RTL">الآثار التالية هي الآثار الجانبية المعروفة لاستخدام زالاكوم:</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًا (قد تصيب أكثر من شخص واحد من بين كل 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير تدريجي في لون عينك عن طريق زيادة نسبة الصبغة البنية في الجزء الملون من العين المعروف باسم القزحية. إذا كانت عيناك مختلطة اللون (بنية-زرقاء، أو بنية-رمادية، أو بنية-صفراء، أو بنية-خضراء) فإن احتمال تعرّضك لهذا التغير يكون أكبر مقارنةً بما إذا كان لون عينيك واحدًا (عينان زرقاوتان أو رماديتان أو خضراوتان أو بنيتان). قد يستغرق حدوث أي تغيرات في لون عينك أعوامًا. قد يكون تغير اللون دائمًا وقد يُلاحظ بشكل أكبر إذا كنت تستخدم زالاكوم في عين واحدة فقط. لا يبدو أن هناك مشكلات مصاحبة لتغير لون العين. لا يستمر التغير في لون العين بعد إيقاف العلاج بزالاكوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل 10 أشخاص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج العين (شعور بحرقان، أو تحبب، أو حكة، أو وخز، أو شعور بوجود جسم غريب في العين) وألم العين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة (قد تصيب ما يصل إلى شخص واحد بين كل 100 شخص):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار العين، عدوى العين (التهاب الملتحمة)، تغيم الرؤية، إدماع العينين، التهاب الجفون، تهيج أو اعتلال سطح العين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي أو الحكة</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL">مثل الأدوية الأخرى التي تُستخدم في العينين، يتم امتصاص زالاكوم (لاتانوبروست وتيمولول) في الدم. معدل حدوث الآثار الجانبية بعد استخدام قطرات العين يكون أقل مقارنةً بمعدل الحدوث عند تناول الأدوية عن طريق الفم أو الحقن على سبيل المثال.</p><p dir="RTL">على الرغم من عدم ملاحظتها مع زالاكوم، لوحظت الآثار الجانبية الإضافية التالية مع الدواءين الموجودين في زالاكوم (لاتانوبروست وتيمولول) ولذلك قد تحدث عند استخدامك لزالاكوم. الآثار الجانبية المدرجة تتضمن التفاعلات الملاحظة مع فئة حاصرات بيتا (مثل تيمولول) عند استخدامها لعلاج حالات العين:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; غثيان، و قيء (غير شائع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تطور عدوى فيروسية في العين سببها فيروس الهربس البسيط (HSV).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات حساسية معممة تتضمن التورم تحت الجلد الذي يمكن أن يحدث في مناطق مثل الوجه والأطراف ويمكن أن يسد المسالك الهوائية مما قد يسبب صعوبة في البلع أو التنفس، الشرى أو الطفح الجلدي المثير للحكة، الطفح الجلدي الموضعي والمُعمم، الحكة، تفاعل حساسية شديد مفاجئ ومهدد للحياة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الجلوكوز في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم (الأرق)، الاكتئاب، الكوابيس، فقدان الذاكرة، الهلاوس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء، والسكتة الدماغية، وانخفاض في إمداد الدم إلى الدماغ، وزيادات في علامات وأعراض الوهن العضلي الوبيل (اضطراب في العضلات)، وإحساس غير طبيعي مثل الشعور بالشكشكة والوخز، والصداع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الجزء الخلفي من العين (التورم البقعي)، وجود تكيس مليء بالسوائل بالجزء الملون من العين (تكيس القزحية)، الحساسية تجاه الضوء (رهاب الضوء)، مظهر غائر للعين (زيادة في عمق تلم العين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات وأعراض تهيج العين (مثل الحرقان، الوخز، الحكة، الإدماع، الاحمرار)، التهاب جفن العين، التهاب القرنية، تغيم الرؤية وانفصال الطبقة الموجودة أسفل الشبكية التي تحتوي على الأوعية الدموية عقب الخضوع لجراحة ترشيحية مما قد يُسبب اضطرابات في الرؤية، انخفاض حساسية القرنية، جفاف العينين، تآكل القرنية (تلف في الطبقة الأمامية من مقلة العين)، ارتخاء الجفن العلوي (مما يجعل العين تبقى شبه مغلقة)، ازدواج الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دكنة الجلد حول العينين، تغيرات في الأهداب والشعر الخفيف حول العينين (زيادة العدد والطول والكثافة ودكنة اللون)، تغيرات في اتجاه نمو الأهداب، تورم حول العين، تورم في الجزء الملون من العين (القزحية/ المشيمية)، تندب سطح العين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صفير/رنين بالأذنين (طنين الأذن).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذبحة الصدرية، تفاقم الذبحة الصدرية لدى المرضى المصابين بالفعل بأمراض قلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بطء معدل نبضات القلب، ألم الصدر، الخفقان (الإحساس بضربات القلب)، التورم (تراكم السوائل)، تغيرات في معدل ضربات القلب أو سرعة نبضاته، فشل القلب الاحتقاني (مرض قلبي مصحوب بضيق التنفس وتورم القدمين والساقين نتيجة لتراكم السوائل)، أحد أنواع اضطراب ضربات القلب، الأزمة القلبية، فشل القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المنخفض، ضعف الدورة الدموية الذي يؤدي إلى خدر وشحوب أصابع اليدين والقدمين، برودة اليدين والقدمين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، تضيّق المسالك الهوائية بالرئتين (بشكل سائد لدى المرضى المصابين بمرض موجود من قبل)، صعوبة التنفس، السعال، الربو، تفاقم حالة الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود اضطرابات في حاسة التذوق، عسر الهضم، الإسهال، جفاف الفم، ألم البطن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر، الطفح الجلدي المصحوب بمظهر ذي لون أبيض فضي (طفح شبيه بالصدفية) أو تفاقم حالة الصدفية، الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل، ألم العضلات غير الناتج عن ممارسة التمرينات، ضعف العضلات، التعب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل الوظائف الجنسية، انخفاض الرغبة الجنسية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في حالات نادرة جدًا، أصيب بعض المرضى الذين يعانون من تلف شديد بالطبقة الشفافة في مقدمة العين (القرنية) ببقع غيمية على القرنية بسبب تراكم الكالسيوم أثناء العلاج.</p><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>المملكة العربية السعودية</strong></li></ul><table dir="rtl" border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><ul><li dir="RTL">الرقم المجاني: 19999</li><li dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</li><li dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</li></ul></td></tr></tbody></table><p dir="RTL">&nbsp;</p><ul><li dir="RTL"><strong>دول الخليج الأخرى</strong></li></ul><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL"><em>&middot;&nbsp;&nbsp; </em><em>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</em></p></td></tr></tbody></table><p dir="RTL">&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">احتفظ بهذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL"><strong>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المُدون بعد الرمز &quot;</strong>EXP<strong>&quot; على العبوة الكرتونية وملصق الزجاجة. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صلاحية المستحضر 36 شهر.</strong></p><p dir="RTL">خزن زجاجات زالاكوم غير المفتوحة في البراد (الثلاجة) (في درجة حرارة تتراوح بين درجتين إلى 8 درجات مئوية). ليس من الضروري أن تخزن الزجاجة في البراد (الثلاجة) بعد فتحها، ولكن لا تخزنها في درجة حرارة أعلى من 25 درجة مئوية.</p><p dir="RTL">بعد الفتح، لا تستخدم هذة الزجاجة لأكثر من أربعة أسابيع. في الأوقات التي لا تستخدم فيها زالاكوم، احفظ الزجاجة في العلبة الكرتونية الخارجية من أجل حمايتها من الضوء.</p><p dir="RTL">لا تتخلص من أي أدوية عبر مياه الصرف أو مع المخلفات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أ-</strong> &nbsp;<strong>ما هي محتويات زالاكوم</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">المادتان الفعالتان هما لاتانوبروست 50 ميكروجرام/مل وتيمولول (في صورة ماليات تيمولول) 5 ملجم/مل</p><p dir="RTL">المكونات الأخرى هي:</p><p dir="RTL">كلوريد البنزالكونيوم</p><p dir="RTL">ثنائي هيدروجين فوسفات الصوديوم أحادي الهيدرات</p><p dir="RTL">فوسفات ثنائي الصوديوم</p><p dir="RTL">كلوريد الصوديوم</p><p dir="RTL">محلول حمض الهيدروكلوريك (لتعديل درجة الحموضة (pH) إلى 6.0)</p><p dir="RTL">محلول هيدروكسيد الصوديوم (لتعديل درجة الحموضة إلى 6.0)</p><p dir="RTL">ماء للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحتوي كل زجاجة على 2.5 مل من قطرات زالاكوم للعين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">زالاكوم هو سائل رائق عديم اللون.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مالك تصريح التسويق: &rlm;أبجون اس ار ال، بوليفارد لا بلين 17 ، 1050 بروكسيل، بلجيكا.&lrm;</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجهة المصنعة: &nbsp;مصنع فايزر ان في، رايكسفيج 12 ، 2870 &lrm;بورس، بلجيكا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            د- تم الموافقة على هذه النشرة بتاريخ يونيو 2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xalacom Eye Drop 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 mL of solution contains 50 micrograms of latanoprost and 6.83 mg of timolol maleate equivalent to 5 mg of timolol.
Excipients with known effect: 
Benzalkonium chloride 0.2 mg/mL
Disodium phosphate Anhydrous, Sodium Dihydrogen Phosphate Monohydrate.
For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops solution.
The solution is a clear and colourless liquid.



            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Therapeutic indications</p><p>Xalacom is indicated in adults (including the elderly) for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta‑blockers or prostaglandin analogues.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adults (including the elderly)</em></p><p>Recommended therapy is one eye drop in the affected eye(s) once daily.</p><p>If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.</p><p><em>Paediatric population</em></p><p>The safety and efficacy of Xalacom in children and adolescents has not been established.</p><p><u>Method of administration</u></p><p><u>&nbsp;</u></p><p>Contact lenses should be removed before instillation of the eye drops and may be reinserted after 15&nbsp;minutes (see section 4.4).</p><p>If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.</p><p>When using nasolacrimal occlusion or closing the eyelids for 2&nbsp;minutes, the systemic absorption is reduced. This may result in a decrease in systemic side effects and an increase in local activity.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Xalacom is contraindicated in patients with:
•	Reactive airway disease including bronchial asthma or a history of bronchial asthma, severe chronic obstructive pulmonary disease.
•	Sinus bradycardia, sick sinus syndrome, sino atrial block, second or third degree atrioventricular block not controlled with pace maker, overt cardiac failure, cardiogenic shock.
•	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Systemic effects</u></p><p>Like other topically applied ophthalmic agents, Xalacom is absorbed systemically. Due to the beta‑adrenergic component timolol, the same types of cardiovascular, pulmonary and other adverse reactions as seen with systemic beta‑adrenergic blocking agents may occur. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. To reduce the systemic absorption, see section&nbsp;4.2.</p><p>&nbsp;</p><p><u>Cardiac disorders</u></p><p>In patients with cardiovascular diseases (e.g. coronary heart disease, Prinzmetal&rsquo;s angina and cardiac failure) and hypotension therapy with beta‑blockers should be critically assessed and the therapy with other active substances should be considered. Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions.</p><p>Due to its negative effect on conduction time, beta‑blockers should only be given with caution to patients with first degree heart block.</p><p>&nbsp;</p><p>Cardiac reactions, and rarely, death in association with cardiac failures have been reported following administration of timolol.</p><p><u>Vascular disorders</u></p><p>Patients with severe peripheral circulatory disturbance/disorders (i.e. severe forms of Raynaud&rsquo;s disease or Raynaud&rsquo;s syndrome) should be treated with caution.</p><p><strong>&nbsp;</strong></p><p><u>Respiratory disorders</u></p><p>Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta‑blockers. Xalacom should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.</p><p><u>Hypoglycemia/diabetes</u></p><p>Beta‑blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with unstable diabetes, as beta‑blockers may mask the signs and symptoms of acute hypoglycaemia.</p><p>&nbsp;</p><p>Beta‑blockers may also mask the signs of hyperthyroidism.</p><p>&nbsp;</p><p><u>Corneal diseases</u></p><p>Ophthalmic beta‑blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.</p><p><em>&nbsp;</em></p><p><u>Other beta‑blocking agents</u></p><p>The effect on intra‑ocular pressure or the known effects of systemic beta‑blockade may be potentiated when timolol is given to the patients already receiving a systemic beta‑blocking agent. The response of these patients should be closely observed. The use of two topical beta‑adrenergic blocking agents is not recommended (see section&nbsp;4.5).</p><p><em>&nbsp;</em></p><p><u>Anaphylactic reactions</u></p><p>While taking beta‑blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.</p><p>&nbsp;</p><p><u>Choroidal detachment</u></p><p>Choroidal detachment has been reported with administration of aqueous suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.</p><p><u>Surgical anaesthesia</u></p><p>Beta‑blocking ophthalmological preparations may block systemic beta‑agonist effects e.g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol.</p><p><em>&nbsp;</em></p><p><u>Concomitant therapy</u></p><p>Timolol may interact with other drugs (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>&nbsp;</u></p><p><u>Other prostaglandin analogues</u></p><p>The concomitant use of two or more prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended (see section&nbsp;4.5).</p><p><u>Iris pigmentation changes </u></p><p>Latanoprost may gradually change eye colour by increasing the amount of brown pigment in the iris. Similar to experience with latanoprost eye drops, increased iris pigmentation was seen in16‑20% of all patients treated with Xalacom for up to one year (based on photographs). This effect has predominantly been seen in patients with mixed coloured irides, i.e. green‑brown, yellow‑brown or blue/grey‑brown, and is due to increased melanin content in the stromal melanocytes of the iris. Typically, the brown pigmentation around the pupil spreads concentrically towards the periphery in affected eyes, but the entire iris or parts of it may become more brownish. In patients with homogeneously blue, grey, green or brown eyes, the change has only rarely been seen during two years of treatment in clinical trials with latanoprost.</p><p>The change in iris colour occurs slowly and may not be noticeable for several months to years and it has not been associated with any symptom or pathological changes.</p><p>No further increase in brown iris pigment has been observed after discontinuation of treatment, but the resultant colour change may be permanent.</p><p>Neither naevi nor freckles of the iris have been affected by the treatment.</p><p>Accumulation of pigment in the trabecular meshwork or elsewhere in the anterior chamber has not been observed but patients should be examined regularly and, depending on the clinical situation, treatment may be stopped if increased iris pigmentation ensues.</p><p>Before treatment is instituted patients should be informed of the possibility of a change in eye colour. Unilateral treatment can result in permanent heterochromia.</p><p><u>Eyelid and eyelash changes</u></p><p>Eyelid skin darkening, which may be reversible, has been reported in association with the use of latanoprost.</p><p>Latanoprost may gradually change eyelashes and vellus hair in the treated eye; these changes include increased length, thickness, pigmentation, and number of lashes or hairs, and misdirected growth of eyelashes. Eyelash changes are reversible upon discontinuation of treatment.</p><p><u>Glaucoma</u></p><p>There is no documented experience with latanoprost in inflammatory, neovascular or chronic angle closure glaucoma, in open angle glaucoma of pseudophakic patients and in pigmentary glaucoma. Latanoprost has no or little effect on the pupil but there is no documented experience in acute attacks of closed angle glaucoma. Therefore it is recommended that Xalacom should be used with caution in these conditions until more experience is obtained.</p><p><u>Herpetic keratitis</u></p><p>Latanoprost should be used with caution in patients with a history of herpetic keratitis, and should be avoided in cases of active herpes simplex keratitis and in patients with a history of recurrent herpetic keratitis specifically associated with prostaglandin analogues.</p><p><u>Macular oedema</u></p><p>Macular oedema, including cystoid macular oedema, has been reported during treatment with latanoprost. These reports have mainly occurred in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular oedema. Xalacom should be used with caution in these patients.</p><p><u>Preservative</u></p><p>Xalacom contains benzalkonium chloride, which is commonly used as a preservative in ophthalmic products. Benzalkonium chloride has been reported to cause punctuate keratopathy and/or toxic ulcerative keratopathy and may cause eye irritation. Close monitoring is required with frequent or prolonged use of Xalacom in dry eye patients, or in conditions where the cornea is compromised.</p><p><u>Contact lenses</u></p><p>Contact lenses may absorb benzalkonium chloride which is known to discolour soft contact lenses. Contact lenses should be removed before applying Xalacom but may be reinserted after 15&nbsp;minutes (see section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific drug interaction studies have been performed with Xalacom.</p><p>There have been reports of paradoxical elevations in intraocular pressure following the concomitant ophthalmic administration of two prostaglandin analogues. Therefore, the use of two or more prostaglandins, prostaglandin analogues, or prostaglandin derivatives is not recommended.</p><p>There is a potential for additive effects resulting in hypotension and/or marked bradycardia when ophthalmic beta‑blockers solution is administered concomitantly with oral calcium channel blockers, beta‑adrenergic blocking agents, antiarrhythmics (including amiodarone), digitalis glycosides, parasympathomimetics, guanethidine.</p><p>&nbsp;</p><p>Potentiated systemic beta blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.</p><p>The effect on intraocular pressure or the known effects of systemic beta‑blockade may be potentiated when Xalacom is given to patients already receiving an oral beta‑adrenergic blocking agent, and the use of two or more topical beta‑adrenergic blocking agents is not recommended.</p><p>Mydriasis resulting from concomitant use of ophthalmic beta‑blockers and adrenaline (epinephrine) has been reported occasionally.</p><p>The hypertensive reaction to sudden withdrawal of clonidine can be potentiated when taking beta‑blockers.</p><p>Beta‑blockers may increase the hypoglycaemic effect of anti‑diabetic agents. Beta‑blockers can mask the signs and symptoms of hypoglycaemia (see section&nbsp;4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p><em>Latanoprost</em></p><p>There are no adequate data from the use of latanoprost in pregnant women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). The potential risk for humans is unknown.</p><p><em>Timolol</em></p><p>There are no adequate data for the use of timolol in pregnant women. Timolol should not be used during pregnancy unless clearly necessary. To reduce the systemic absorption, see section&nbsp;4.2.</p><p>Epidemiological studies have not revealed malformative effects but show a risk for intra uterine growth retardation when beta‑blockers are administered by the oral route. In addition, signs and symptoms of beta‑blockade (e.g. bradycardia, hypotension, respiratory distress and hypoglycaemia) have been observed in the neonate when beta‑blockers have been administered until delivery. If Xalacom is administered until delivery, the neonate should be carefully monitored during the first days of life.</p><p>&nbsp;</p><p>Consequently Xalacom should not be used during pregnancy (see section&nbsp;5.3).</p><p><u>Breast‑feeding</u></p><p>Beta‑blockers are excreted in breast milk. However, at therapeutic doses of timolol in eye drops it is not likely that sufficient amounts would be present in breast milk to produce clinical symptoms of beta‑blockade in the infant. To reduce the systemic absorption, see section&nbsp;4.2.</p><p>&nbsp;</p><p>Latanoprost and its metabolites may pass into breast milk. Xalacom should therefore not be used in women who are breast feeding.</p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Neither latanoprost nor timolol have been found to have any effect on male or female fertility<strong><em> </em></strong>in animal studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>4.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effects on ability to drive and use machines</p><p>Xalacom has minor influence on the ability to drive and use machines. In common with other eye preparations, instillation of eye drops may cause transient blurring of vision. Until this has resolved, patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of safety profile:</p><p>&nbsp;</p><p>For latanoprost, the majority of adverse reactions relate to the ocular system. In data from the extension phase of the Xalacom pivotal trials, 16‑20% of patients developed increased iris pigmentation, which may be permanent. In an open 5&nbsp;year latanoprost safety study, 33% of patients developed iris pigmentation (see section&nbsp;4.4). Other ocular adverse reactions are generally transient and occur on dose administration. For timolol, the most serious adverse reactions are systemic in nature, including bradycardia, arrhythmia, congestive heart failure, bronchospasm and allergic reactions.</p><p>Like other topically applied ophthalmic drugs, timolol is absorbed into the systemic circulation. This may cause similar undesirable effects as seen with systemic beta blocking agents. Incidence of systemic ADRs after topical ophthalmic administration is lower than for systemic administration. Listed adverse reactions include reactions seen within the class of ophthalmic beta‑blockers.</p><p>&nbsp;</p><p>Treatment related adverse reactions seen in clinical trials with Xalacom are listed below.</p><p>Adverse reactions are categorized by frequency as follows: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000), not known (frequency cannot be estimated from the available data).</p><p><strong>Table 1: Adverse reactions seen in Xalacom trials</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Very common (&ge;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p><p><strong>&ge; 1/100 to &lt; 1/10</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p><p><strong>&ge; 1/1,000 to</strong></p><p><strong>&lt; 1/100</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Iris hyperpigmentation</p></td><td style="vertical-align:top"><p>Eye pain, eye irritation (including stinging, burning, itching, foreign body sensation)</p></td><td style="vertical-align:top"><p>Corneal disorders, conjunctivitis, blepharitis, eye hyperaemia, vision blurred, lacrimation increased</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash, pruritus</p></td></tr></tbody></table><p>&nbsp;</p><p>Additional adverse reactions have been reported specific to the use of the individual components of Xalacom in either clinical studies, spontaneous reports or in the available literature.</p><p>For latanoprost, the adverse reactions were as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:613px"><thead><tr><td colspan="2" style="vertical-align:top"><p>Table 2 Adverse Reaction: Latanoprost</p></td></tr><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Adverse Reactions</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Herpetic keratitis</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Eyelash and vellus hair changes of the eyelid (increased length, thickness, pigmentation, and number of eyelashes); punctate keratitis, periorbital oedema; iritis; uveitis; macular oedema including cystoid macular oedema; dry eye; keratitis; corneal oedema; corneal erosion; trichiasis; iris cyst; photophobia; periorbital and lid changes resulting in deepening of the eyelid sulcus; eyelid oedema; localised skin reaction on the eyelids; pseudopemphigoid of the ocular conjunctiva<sup>+</sup>; darkening of the palpebral skin</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina; angina unstable; palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Asthma; asthma aggravation; dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea; vomiting</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia; arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Chest pain</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>* Identified post marketing with an estimated frequency of uncommon</p><p><sup>+ </sup>May be potentially related to the preservative benzalkonium chloride</p></td></tr></tbody></table><p>&nbsp;</p><p>For timolol, the adverse reactions were as follows:</p><table border="0" cellspacing="0" cellpadding="0" style="width:613px"><thead><tr><td colspan="2" style="vertical-align:top"><p>Table 3 Adverse Reaction: timolol maleate (ocular administration)</p></td></tr><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Adverse Reactions</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Systemic allergic reactions including anaphylactic reaction, angioedema, urticaria, localised and generalised rash, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Hypoglycaemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Memory loss, insomnia, depression, nightmares, hallucinations</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Cerebrovascular accident, cerebral ischaemia, dizziness, increases in signs and symptoms of myasthenia gravis, paraesthesia, headache, syncope</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Choroidal detachment following filtration surgery (see section&nbsp;4.4), corneal erosion, keratitis, diplopia, decreased corneal sensitivity, signs and symptoms of ocular irritation (e.g., burning, stinging, itching, tearing and redness), dry eyes, ptosis, blepharitis, blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Tinnitus</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Cardiac arrest, cardiac failure, atrioventricular block, congestive heart failure, chest pain, arrhythmia, bradycardia, oedema, palpitations</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Cold hands and feet, hypotension, Raynaud&rsquo;s phenomenon</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchospasm (predominately in patients with pre‑existing bronchospastic disease), cough, dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain, vomiting, diarrhoea, dry mouth, dysgeusia, dyspepsia, nausea</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Skin rash, psoriasiform rash, exacerbation of psoriasis, alopecia</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Sexual dysfunction, decreased libido</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia, fatigue</p></td></tr></tbody></table><p>&nbsp;</p><p>Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.</p><p><u>Reporting of suspected adverse reactions </u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via local reporting system.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>To Report side effects:</strong></p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>National Pharmacovigilance Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No data are available in humans with regard to overdose with Xalacom.</p><p><u>Symptoms</u></p><p>Symptoms of systemic<strong> </strong>timolol overdose are: bradycardia, hypotension, bronchospasm and cardiac arrest.</p><p>Apart from ocular irritation and conjunctival hyperaemia, no other ocular or systemic side effects are known if latanoprost is overdosed.</p><p><u>Treatment</u></p><p>If symptoms of overdose occur the treatment should be symptomatic and supportive.</p><p>If accidentally ingested orally the following information may be useful: Studies have shown that timolol does not dialyse readily. Gastric lavage if needed. Latanoprost is extensively metabolised during the first pass through the liver. Intravenous infusion of 3&nbsp;micrograms/kg in healthy volunteers induced no symptoms, but a dose of 5.5‑10&nbsp;micrograms/kg caused nausea, abdominal pain, dizziness, fatigue, hot flushes and sweating. These events were mild to moderate in severity and resolved without treatment, within 4&nbsp;hours after terminating the infusion.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:</p><p>Ophthalmological‑betablocking agents‑timolol, combinations</p><p>ATC code: S01ED51</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Xalacom consists of two components: latanoprost and timolol maleate. These two components decrease elevated intraocular pressure (IOP) by different mechanisms of action and the combined effect results in additional IOP reduction compared to either compound administered alone.</p><p>Latanoprost, a prostaglandin F<sub>2</sub><sub>a</sub> analogue, is a selective prostanoid FP receptor agonist that reduces the IOP by increasing the outflow of aqueous humour. The main mechanism of action is increased uveoscleral outflow. Additionally, some increase in outflow facility (decrease in trabecular outflow resistance) has been reported in man. Latanoprost has no significant effect on the production of aqueous humour, the blood‑aqueous barrier or the intraocular blood circulation. Chronic treatment with latanoprost in monkey eyes, which had undergone extracapsular lens extraction did not affect the retinal blood vessels as determined by fluorescein angiography. Latanoprost has not induced fluorescein leakage in the posterior segment of pseudophakic human eyes during short term treatment.</p><p>Timolol is a beta‑1 and beta‑2 (non‑selective) adrenergic receptor blocking agent that has no significant intrinsic sympathomimetic, direct myocardial depressant or membrane‑stabilising activity.<em><sup> </sup></em>Timolol lowers IOP by decreasing the formation of aqueous in the ciliary epithelium.</p><p>The precise mechanism of action is not clearly established, but inhibition of the increased cyclic AMP synthesis caused by endogenous beta‑adrenergic stimulation is probable.<sup> </sup>Timolol has not been found to significantly affect the permeability of the blood‑aqueous barrier to plasma proteins. In rabbits, timolol was without effect on the regional ocular blood flow after chronic treatment.<sup> </sup></p><p><u>Pharmacodynamic effects</u></p><p><strong>&nbsp;</strong></p><p><em>Clinical </em><em>efficacy and safety</em></p><p>In dose finding studies, Xalacom produced significantly greater decreases in mean diurnal IOP compared to latanoprost and timolol administered once daily as monotherapy. In two well controlled, double masked six‑month clinical studies the IOP reducing effect of Xalacom was compared with latanoprost and timolol monotherapy in patients with an IOP of at least 25&nbsp;mm&nbsp;Hg or greater. Following a 2‑4&nbsp;week run‑in with timolol (mean decrease in IOP from enrollment of 5&nbsp;mm&nbsp;Hg), additional decreases in mean diurnal IOP of 3.1, 2.0 and 0.6&nbsp;mm&nbsp;Hg were observed after 6 months of treatment for Xalacom, latanoprost and timolol (twice daily), respectively. The IOP lowering effect of Xalacom was maintained in 6 month open label extension of these studies.</p><p>Existing data suggest that evening dosing may be more effective in IOP lowering than morning dosing. However, when considering a recommendation of either morning or evening dosing, sufficient consideration should be given to the lifestyle of the patient and their likely compliance.</p><p>It should be kept in mind that in case of insufficient efficacy of the fixed combination, results from studies indicate that the use of unfixed administration of timolol bid and latanoprost once a day might be still efficient.</p><p>&nbsp;</p><p>Onset of action of Xalacom is within one hour and maximal effect occurs within six to eight hours. Adequate IOP reducing effect has been shown to be present up to 24&nbsp;hours post dosage after multiple treatments.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Latanoprost<sup> </sup></u></p><p><em>Absorption</em></p><p>Latanoprost is an isopropyl ester prodrug, which per se is inactive but after hydrolysis by esterases in the cornea to the acid of latanoprost, becomes biologically active. The prodrug is well absorbed through the cornea and all drug that enters the aqueous humor is hydrolysed during the passage through the cornea.</p><p>&nbsp;</p><p><em>Distribution</em></p><p>Studies in man indicate that the maximum concentration in the aqueous humour, approximately 15‑30&nbsp;ng/mL, is reached about 2&nbsp;hours after topical administration of latanoprost alone.After topical application in monkeys latanoprost is distributed primarily in the anterior segment, the conjunctiva and the eye lids.</p><p>&nbsp;</p><p>The acid of latanoprost has a plasma clearance of 0.40 l/h/kg and a small volume of distribution, 0.16 l/kg, resulting in a rapid half-life in plasma, 17&nbsp;minutes. After topical ocular administration the systemic bioavailability of the acid of latanoprost is 45%. The acid of latanoprost has a plasma protein binding of 87%.</p><p><em>Biotransformation and elimination</em><br />There is practically no metabolism of the acid of latanoprost in the eye. The main metabolism occurs in the liver. The main metabolites, the 1,2‑dinor and 1,2,3,4‑tetranor metabolites, exert no or only weak biological activity in animal studies and are excreted primarily in the urine.</p><p><u>Timolol</u></p><p><em>Absorption and distribution</em><br />The maximum concentration of timolol in the aqueous humour is reached about 1&nbsp;hour after topical administration of eye drops. Part of the dose is absorbed systemically and a maximum plasma concentration of 1&nbsp;ng/mL is reached 10‑20&nbsp;minutes after topical administration of one eye drop to each eye once daily (300&nbsp;micrograms/day).</p><p><em>Biotransformation</em><br />The half-life of timolol in plasma is about 6&nbsp;hours. Timolol is extensively metabolised in the liver.</p><p><em>Elimination</em><br />The metabolites are excreted in the urine together with some unchanged timolol.</p><p><u>Xalacom</u></p><p><em>Pharmacokinetic/pharmacodynamic relationship</em></p><p>No pharmacokinetic interactions between latanoprost and timolol were observed, although there was an approximate 2‑fold increased concentration of the acid of latanoprost in aqueous humour 1‑4&nbsp;hours after administration of Xalacom compared to monotherapy</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ocular and systemic safety profile of the individual components is well established. No adverse ocular or systemic effects were seen in rabbits treated topically with the fixed combination or with concomitantly administered latanoprost and timolol ophthalmic solutions. Safety pharmacology, genotoxicity and carcinogenicity studies with each of the components revealed no special hazards for humans. Latanoprost did not affect corneal wound healing in the rabbit eye, whereas timolol inhibited the process in the rabbit and the monkey eye when administered more frequently than once a day.</p><p>For latanoprost, no effects on male and female fertility in rats and no teratogenic potential in rats and rabbits have been established. No embryotoxicity was observed in rats after intravenous doses of up to 250&nbsp;micrograms/kg/day. However, latanoprost caused embryofetal toxicity, characterised by increased incidence of late resorption and abortion and by reduced foetal weight, in rabbits at intravenous doses of 5&nbsp;micrograms/kg/day (approximately 100 times the clinical dose) and above. Timolol showed no effects on male and female fertility in rats or teratogenic potential in mice, rats and rabbits.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>6.1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; List of excipients</p><p>Benzalkonium chloride</p><p>Disodium phosphate Anhydrous</p><p>Sodium Dihydrogen Phosphate Monohydrate</p><p>Sodium chloride</p><p>Hydrochloric acid (for adjustment to pH 6.0)</p><p>Sodium hydroxide (for adjustment to pH 6.0)</p><p>Water for injection</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In vitro studies have shown that precipitation occurs when eye drops containing thiomersal are mixed with Xalatan. If such drugs are used concomitantly with Xalacom, the eye drops should be administered with an interval of at least five minutes.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Do not use Xalacom after the expiry date which is stated on the carton / bottle label after EXP:The expiry date refers to the last day of that month.

Before first opening: 36 Months.
After opening of container: 4 weeks.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before first opening: store in a refrigerator (2&deg;C &ndash; 8&deg;C).</p><p>After first opening: do not store above 25&deg;C. Use within 4 weeks (see section 6.3).</p><p>Keep the bottle in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Dropper container (5&nbsp;mL) of polyethylene with&nbsp;a screw cap and tamper evident polyethylene overcap.</p><p>Each bottle contains 2.5&nbsp;mL eye drop solution.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The tamper evident overcap should be removed before use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Upjohn SRL/BV, Belgium, 




            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>